Precision Medicine

被引：14
作者：
Pacanowski, M. [1 ]
Huang, S. M. [1 ]
机构：
[1] US FDA, Off Clin Pharmacol, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷 / 02期
关键词：
PATIENT;
D O I：
10.1002/cpt.296
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：124 / 129
页数：6
相关论文
共 15 条
  • [1] [Anonymous], 2015, WHIT HOUS FACT SHEET
  • [2] Direct-to-consumer genetic testing: Perspectives on its value in healthcare
    Delaney, S. K.
    Christman, M. F.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 146 - 148
  • [3] Real-world data in the molecular erafinding the reality in the real world
    Dickson, D. J.
    Pfeifer, J. D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 186 - 197
  • [4] Integrated patient and tumor genetic testing for individualized cancer therapy
    Hertz, D. L.
    McLeod, H. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 143 - 146
  • [5] Therapeutic drug monitoring: A patient management tool for precision medicine
    Jang, S. H.
    Yan, Z.
    Lazor, J. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 148 - 150
  • [6] Advancing Pharmacogenomics as a Component of Precision Medicine: How, Where, and Who?
    Johnson, J. A.
    Weitzel, K. W.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 154 - 156
  • [7] Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
    Kalman, L. V.
    Agundez, J. A. G.
    Appell, M. Lindqvist
    Black, J. L.
    Bell, G. C.
    Boukouvala, S.
    Bruckner, C.
    Bruford, E.
    Caudle, K.
    Coulthard, S. A.
    Daly, A. K.
    Del Tredici, A. L.
    den Dunnen, J. T.
    Drozda, K.
    Everts, R. E.
    Flockhart, D.
    Freimuth, R. R.
    Gaedigk, A.
    Hachad, H.
    Hartshorne, T.
    Ingelman-Sundberg, M.
    Klein, T. E.
    Lauschke, V. M.
    Maglott, D. R.
    McLeod, H. L.
    McMillin, G. A.
    Meyer, U. A.
    Mueller, D. J.
    Nickerson, D. A.
    Oetting, W. S.
    Pacanowski, M.
    Pratt, V. M.
    Relling, M. V.
    Roberts, A.
    Rubinstein, W. S.
    Sangkuhl, K.
    Schwab, M.
    Scott, S. A.
    Sim, S. C.
    Thirumaran, R. K.
    Toji, L. H.
    Tyndale, R. F.
    van Schaik, R. H. N.
    Whirl-Carrillo, M.
    Yeo, K. T. J.
    Zanger, U. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 172 - 185
  • [8] Industry perspectives on biomarker qualification
    Lavezzari, G.
    Womack, A. W.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 208 - 213
  • [9] Providing Access to Genomic Variant Knowledge in a Healthcare Setting: A Vision for the ClinGen Electronic Health Records Workgroup
    Overby, C. L.
    Heale, B.
    Aronson, S.
    Cherry, J. M.
    Dwight, S.
    Milosavljevic, A.
    Nelson, T.
    Niehaus, A.
    Weaver, M. A.
    Ramos, E. M.
    Williams, M. S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 157 - 160
  • [10] Polyallelic structural variants can provide accurate, highly informative genetic markers focused on diagnosis and therapeutic targets: Accuracy vs. Precision
    Roses, A. D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (02) : 169 - 171
12